UNSPSC 51282209: Flomoxef sodium

This classification denotes a cephalosporin antibiotic with the molecular structure C15H17F2N6O7S2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 445HIB8XNF chemically known as 5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((difluoromethyl)thio)acetyl)amino)-3-(((1-(2-hydroxyethyl)-1h-tetrazol-5-yl)thio)methyl)-7-methoxy-8-oxo-, sodium salt (1:1), (6r,7r)-, but more commonly known as flomoxef sodium, which bears US NIH Compound Identifier 443982.

UNSPSC 51282209 Flomoxef sodium is a Commodity code covering pharmaceutical products that state and local governments procure through warehouse and inventory supply contracts. The recent opportunities tagged to this code show limited direct relevance to flomoxef sodium specifically; instead, state and local agencies are acquiring a broader range of pharmaceutical products—including antibiotics, naloxone, and drug deactivation systems—through cooperative purchasing vehicles and competitive sealed bids. Issuing bodies include state health departments and county health authorities, which leverage piggyback contracts and consortium arrangements (such as MMCAP Infuse) to aggregate demand and consolidate vendor relationships with pharmaceutical distributors and manufacturers.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over a three-year term with renewal options; the procurement was an Invitation for Bid process. Seminole County, Florida released an IFB on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023. Neither solicitation targets flomoxef sodium directly, signaling that this code sees limited discrete activity at the state and local level relative to broader pharmaceutical supply contracts.